NCT04589260View on ClinicalTrials.gov

TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis

PHASE1TerminatedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

May 6, 2021

Study Completion Date

October 4, 2021

Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
DRUG

TD-1058

Study drug to be administered by oral inhalation

DRUG

Placebo

Placebo to be administered by oral inhalation

Trial Locations (1)

M23 9QZ

Theravance Biopharma Investigational Site, Manchester

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY

NCT04589260 - TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter